LEXICON PHARMACEUTICALS, INC. 8K

Lexicon Pharmaceuticals reported Q2 2026 results showing a net loss alongside strengthened liquidity, while announcing completion of Phase 3 SONATA-HCM enrollment, progress toward a Q4 2026 ZYNQUISTA NDA resubmission, advancement of partnered programs, and a new $100 million Hercules Capital loan facility.

On August 6, 2026, Lexicon Pharmaceuticals, Inc. reported its financial results for the quarter ended June 30, 2026, highlighting a sharp year-over-year revenue decline due to the absence of prior-year licensing revenue, higher R&D and SG&A expenses that resulted in a $31.8 million net loss, and a strengthened cash position following equity financing and a new $100 million loan facility with Hercules Capital; the company also provided operational and clinical updates including completion of enrollment in its pivotal Phase 3 SONATA-HCM trial of sotagliflozin for hypertrophic cardiomyopathy with top-line data expected in Q1 2027, progress toward a Q4 2026 NDA resubmission for ZYNQUISTA in type 1 diabetes supported by external study data, ongoing global regulatory and commercial activities for sotagliflozin via licensee Viatris, early-stage clinical development and substantial milestone potential under its LX9851 obesity collaboration with Novo Nordisk, and continued strategic planning for its neuropathic pain candidate pilavapadin (LX9211).

Filing Facts

CIK

1062822

Ticker

LXRX

Form

8K

Source Type

fda

Accession

0001062822-26-000112

Alert Tier

6